ArticleTranslational lung cancer research2026
Tool-in-lesion confirmation and diagnostic yield of digital tomosynthesis-integrated robotic bronchoscopic biopsy of lung nodules.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transbronchial lung biopsy with electromagnetic navigation (EMN) has reported diagnostic yield of 60-70%. Newer systems with active robotic control overcome the limitations of older manually controlled systems, but accuracy may still be limited by computed tomography (CT)-to-body divergence. The novel digital tomosynthesis-integrated Galaxy SystemTM (Noah Medical) incorporating Tool-in-Lesion Tomography (TiLT Methods: Between September 2023 and October 2024, data of 27 lung nodules in 25 patients who underwent peripheral lung nodule biopsy using the Galaxy System Results: Seventeen out of 27 nodules were solid, the rest being mixed ground glass opacities (GGOs). Bronchus sign was positive in 66.7% of the patients. A mean of 3.1 cycles of digital tomosynthesis (range, 2-6 cycles) was required to achieve TIL on tomography before CBCT confirmation. Procedural success, defined as ability to complete biopsy using he robotic system, was 96.3%. TIL/tool-touching-lesion (TTL) was confirmed by CBCT in 25/27 nodules (92.6%), with 16/27 (59.3%) showing center-strike. Conservative diagnostic yield was 84%, consisting of 16 definitive malignant and 5 benign specific diagnoses. There were no complications. Conclusions: Robotic bronchoscopy with digital tomosynthesis is a safe and feasible method to reduce CT-to-body divergence and provide TIL confirmation, with good diagnostic yield.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.